ResMed Inc. (RMD)
|Net Income (ttm)||457.24M|
|Trading Day||May 10|
|Day's Range||194.35 - 196.48|
|52-Week Range||148.29 - 223.99|
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
ResMed (RMD) delivered earnings and revenue surprises of 6.56% and -2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Year-over-year operating profit up 3%, non-GAAP operating profit up 2%
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wedn...
Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
Nyxoah Reports Full Year 2020 Results
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, Ap...
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
The stock of ResMed (NYSE:RMD, 30-year Financials) appears to be modestly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stoc...
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer and Brett Sandercock, chief financial officer, will participate in a virtual f...
New Survey Shows Stress Over the Past Year Is Negatively Impacting the Quality of Sleep for Half of Americans
SAN DIEGO--(BUSINESS WIRE)---- $RMD #sleep--ResMed's 2021 U.S. Consumer Sleep Survey reveals how many Americans have symptoms of a common sleep disorder, but aren't concerned about them.
These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first ...
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
PAHC vs. RMD: Which Stock Is the Better Value Option?
ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.
ResMed Inc. (RMD) CEO Mick Farrell on Q2 2021 Results - Earnings Call Transcript
ResMed (RMD) delivered earnings and revenue surprises of 15.57% and 3.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ResMed (NYSE:RMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of ...
SAN DIEGO--(BUSINESS WIRE)--ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended December 31, 2020. Second Quarter 2021 Highlights All...
On Thursday, January 28, ResMed (NYSE:RMD) will release its latest earnings report. Decipher the announcement with Benzinga's help.
Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.
QDEL vs. RMD: Which Stock Is the Better Value Option?
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bols...
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2021 on Thursday, January 28, 2021, a...
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, ...
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely to witness...
Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Final Trades: Home Depot, Zimmer Holdings, Tractor Supply & more
The "Halftime Report" traders give their top picks to watch for the second half.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi ...
Is (RMD) Outperforming Other Medical Stocks This Year?
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
ResMed CEO on digital health, treating patients outside the hospital
ResMed CEO Michael Farrell broke down how the medical equipment benefits from the emerging digital medicine space.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
3 Stocks to Capitalize on Promising Medical Products Industry
Is (RMD) Outperforming Other Medical Stocks This Year?
Dividend growth strategy is a major source of consistent income for investors in any type of market, though it doesn't offer dramatic price appreciation.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, di... [Read more...]
Medical Instruments & Supplies
|IPO Date |
Jun 2, 1995
|Stock Exchange |
|Ticker Symbol |
In 2020, ResMed's revenue was $2.96 billion, an increase of 13.44% compared to the previous year's $2.61 billion. Earnings were $621.67 million, an increase of 53.65%.
According to 10 analysts, the average rating for ResMed stock is "Hold." The 12-month stock price forecast is 211.40, which is an increase of 8.28% from the latest price.